Detalhe da pesquisa
1.
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
N Engl J Med
; 385(21): 1941-1950, 2021 11 18.
Artigo
Inglês
| MEDLINE | ID: mdl-34706189
2.
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
JAMA
; 327(13): 1236-1246, 2022 04 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35285853
3.
A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults.
J Clin Psychopharmacol
; 38(4): 336-343, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-29912786
4.
Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
J Clin Psychopharmacol
; 33(1): 45-54, 2013 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-23277268
5.
Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study.
Future Virol
; 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-38074312
6.
Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19.
J Patient Rep Outcomes
; 7(1): 92, 2023 09 13.
Artigo
Inglês
| MEDLINE | ID: mdl-37702920
7.
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial.
Open Forum Infect Dis
; 10(8): ofad354, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37577112
8.
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AR19, a Manipulation-Resistant Formulation of Amphetamine Sulfate, in Adults With Attention-Deficit/Hyperactivity Disorder.
J Clin Psychiatry
; 82(5)2021 08 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34428356
9.
Post hoc Responder and Remission Analyses from Two Studies of SHP465 Mixed Amphetamine Salts Extended-Release Among Adults with Attention-Deficit/Hyperactivity Disorder.
J Child Adolesc Psychopharmacol
; 30(7): 427-438, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32423239
10.
A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders.
J Child Adolesc Psychopharmacol
; 28(1): 47-54, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29035574
11.
A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.
J Psychopharmacol
; 31(9): 1190-1203, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28857719
12.
Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients.
J Child Adolesc Psychopharmacol
; 27(6): 526-534, 2017 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-28333546
13.
Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
CNS Neurosci Ther
; 22(7): 546-57, 2016 07.
Artigo
Inglês
| MEDLINE | ID: mdl-26922462
14.
Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.
J Am Acad Child Adolesc Psychiatry
; 44(9): 915-24, 2005 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-16113620
15.
Self-regulation and inhibition in comorbid ADHD children: an evaluation of executive functions.
J Atten Disord
; 8(3): 96-108, 2005 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-16009658
16.
Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study.
Expert Rev Neurother
; 15(11): 1353-66, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26488905
17.
Self-reported vs. actual use of medications in chronic pain patients.
Pain
; 12(3): 285-294, 1982 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-6123102
18.
GW320659 for the treatment of attention-deficit/hyperactivity disorder in children.
J Am Acad Child Adolesc Psychiatry
; 41(8): 914-20, 2002 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-12162627
19.
Addressing attention-deficit/hyperactivity disorder in the workplace.
Postgrad Med
; 126(5): 25-30, 2014 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25295647
20.
Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.
Clin Neuropharmacol
; 34(2): 51-60, 2011.
Artigo
Inglês
| MEDLINE | ID: mdl-21406998